Doximity, Inc. (DOCS)
Automate Your Wheel Strategy on DOCS
With Tiblio's Option Bot, you can configure your own wheel strategy including DOCS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DOCS
- Rev/Share 3.0282
- Book/Share 5.7476
- PB 9.9242
- Debt/Equity 0.0114
- CurrentRatio 6.9669
- ROIC 0.1737
- MktCap 10713603254.0
- FreeCF/Share 1.4241
- PFCF 39.9393
- PE 48.1402
- Debt/Assets 0.0098
- DivYield 0
- ROE 0.2238
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | DOCS | BTIG Research | Neutral | Buy | -- | $80 | June 2, 2025 |
| Upgrade | DOCS | Leerink Partners | Market Perform | Outperform | $60 | $90 | Feb. 7, 2025 |
| Upgrade | DOCS | Piper Sandler | Neutral | Overweight | $31 | $78 | Feb. 7, 2025 |
| Initiation | DOCS | Stephens | -- | Equal Weight | -- | $55 | Dec. 20, 2024 |
| Initiation | DOCS | Mizuho | -- | Neutral | -- | $55 | Dec. 4, 2024 |
| Upgrade | DOCS | Barclays | Equal Weight | Overweight | $35 | $52 | Oct. 15, 2024 |
News
Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage.
Read More
OGN or DOCS: Which Is the Better Value Stock Right Now?
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical Services sector might want to consider either Organon (OGN) or Doximity (DOCS). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.
Read More
DOCS Boosts Client Retention via Workflow Integration and AI Tools
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Doximity strengthens client loyalty by embedding AI tools and clinical workflows into its platform for medical professionals.
Read More
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm
Published: June 09, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 9, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Doximity caused the company to misrepresent or fail to disclose material information concerning the Company's business and operations.
Read More
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.
Read More
Doximity Declines 4.4% in a Month: How to Play the Stock Now?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Over the past month, Doximity's DOCS shares have lost approximately 4.4% despite the company reporting solid fourth-quarter fiscal 2025 results with $138.3 million in revenues and a 50% adjusted EBITDA margin. For fiscal 2025, revenues totaled $570.4 million, up 20% year over year, with adjusted EBITDA rising 36% to $313.8 million and margin expanding to 55%.
Read More
The “English Warren Buffett” Dumped Most of His Portfolio, But Bought Big Into These 3 Stocks
Published: June 04, 2025 by: 24/7 Wall Street
Sentiment: Positive
His concentrated portfolio strategy, focusing on high-quality, long-term holdings, reflects a disciplined, tech-heavy investment approach.
Read More
Doximity Rides on Telehealth Demand: Will This Drive Sales Further?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
DOCS posts strong Q4 revenue growth and record user engagement as demand for telehealth and AI tools hits new highs.
Read More
Which Telehealth Stock Should You Be Targeting?
Published: June 03, 2025 by: Schaeffers Research
Sentiment: Positive
Hims & Hers Health Inc (NYSE:HIMS) stock made waves in premarket trading, after the telehealth firebrand announced the pending acquisition of ZAVA, a European digital health platform.
Read More
Doximity, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Doximity, Inc. (NYSE: DOCS) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors.
Read More
Doximity Stock Plunges Despite Q4 Earnings & Sales Beat, Margins Up
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
DOCS reports robust growth in unique active users and sales of workflow tools, driving the top and bottom lines. First-quarter fiscal 2026 sales outlook below estimates.
Read More
DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Doximity, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Published: May 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Doximity, Inc. (NYSE: DOCS) on behalf of long-term stockholders following a class action complaint that was filed against Doximity on April 17, 2024 with a Class Period from February 9, 2022, to April 1, 2024. Our investigation concerns whether the board of directors of Doximity have breached their fiduciary duties to the company.
Read More
Doximity, Inc. (DOCS) Q4 2025 Earnings Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Doximity, Inc. (NYSE:DOCS ) Q4 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Perry Gold - Head of IR Jeff Tangney - Co-Founder and CEO Anna Bryson - CFO Nate Gross - Co-Founder and CSO Conference Call Participants Brian Peterson - Raymond James Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI Ryan MacDonald - Needham Jared Haase - William Blair Allen Lutz - Bank of America Scott Schoenhaus - KeyBanc Ann Samuel - JPMorgan Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler Steven Veliquette - Mizuho Securities Jeff Garro - Stephens David …
Read More
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm
Published: May 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.
Read More
Doximity Q4 Earnings Likely to Reflect Strong Product Momentum
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.
Read More
Doximity: Strong Fundamentals And Pharma Tailwinds Meet An Overpriced Valuation
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Doximity is experiencing strong user engagement growth, driven by demand from medical prescribers and pharmaceutical marketers. Pharma marketing, Doximity's largest opportunity, is fueling sustained momentum alongside the early success of new platform tools. Integrated features like the client portal drive network effects and boost customer stickiness through real-time marketing insights.
Read More
5 Momentum Stocks to Buy for April Despite a Disappointing March
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Five stocks have strong momentum for April. These are: APP, MRVL, DOCS, RDDT, VEEV.
Read More
3 Medical Services Industry Stocks to Buy as AI Fuels Growth
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Medical - Services industry is undergoing a transformation on massive artificial intelligence adoption. COR, DOCS and MD are set to gain the most.
Read More
Buy These 5 Top-Ranked Stocks to Play Likely Earnings Beat
Published: March 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Top-ranked stocks Doximity (DOCS), Life Time Group Holdings (LTH), Adtalem Global Education (ATGE), BioMarin Pharmaceutical (BMRN) and Iridium Communications (IRDM) are likely to beat on the bottom line in their upcoming releases.
Read More
Is Doximity (DOCS) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Doximity (DOCS) possesses solid growth attributes, which could help it handily outperform the market.
Read More
5 Top-Ranked Stocks Poised for an Earnings Beat
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Top-ranked stocks Tenet Healthcare (THC), Fortinet (FTNT), Lyft (LYFT), Garmin (GRMN) and Doximity (DOCS) are likely to beat on the bottom line in their upcoming releases.
Read More
Doximity: Rating Downgrade As Near-Term Upside Is Priced In
Published: February 14, 2025 by: Seeking Alpha
Sentiment: Positive
I downgraded Doximity from buy to hold due to expected growth slowdown and current high valuation at 40.5x forward EBITDA. DOCS reported strong Q3 performance with $168.6 million revenue, 25% y/y growth, and 93.3% gross margin, driven by high pharma client demand. New ad products grew over 100% y/y, now contributing >20% of pharma revenue, showing strong underlying demand and expanding advertiser engagement.
Read More
Doximity Momentum, Big Money Support Stays Strong
Published: February 14, 2025 by: FXEmpire
Sentiment: Positive
Shares of Doximity, Inc. (DOCS) jump on business growth, investor inflows.
Read More
Doximity (DOCS) is an Incredible Growth Stock: 3 Reasons Why
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Doximity (DOCS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
Why Doximity (DOCS) Might be Well Poised for a Surge
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Doximity (DOCS) is a Great Momentum Stock: Should You Buy?
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Doximity (DOCS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
About Doximity, Inc. (DOCS)
- IPO Date 2021-06-24
- Website https://www.doximity.com
- Industry Medical - Healthcare Information Services
- CEO Mr. Jeffrey A. Tangney
- Employees 827